Related Experiment Video

Updated: Aug 11, 2026

Candida albicans Biofilm Chip (CaBChip) for High-throughput Antifungal Drug Screening
08:05

Candida albicans Biofilm Chip (CaBChip) for High-throughput Antifungal Drug Screening

Published on: July 18, 2012

Amphotericin B

A Lemke1, A F Kiderlen, O Kayser

  • 1Institute of Pharmacy, Pharmaceutical Technology, Biotechnology, and Quality Management, Freie Universität Berlin, Berlin 12169, Germany.

Applied Microbiology and Biotechnology
|April 12, 2005
PubMed

Insights

Amphotericin B is an effective antifungal drug, but its kidney toxicity limits use. New formulations aim to reduce side effects, improving safety for patients with invasive fungal infections.

Area of Science:

  • Pharmacology
  • Mycology
  • Drug Development

Background:

  • Invasive fungal infections pose significant risks to immunocompromised patients, including those with AIDS, transplant recipients, and cancer patients undergoing chemotherapy.
  • Amphotericin B is a highly effective antifungal medication, but its clinical utility is constrained by dose-dependent nephrotoxicity.
  • Development of novel pharmaceutical formulations is crucial to mitigate Amphotericin B's adverse effects and enhance patient safety.

Purpose of the Study:

  • To review the molecular genetics, pharmacology, toxicology, and clinical data of Amphotericin B.
  • To discuss the advancements and clinical relevance of innovative Amphotericin B formulations.
  • To provide a comprehensive overview of Amphotericin B and its improved delivery systems.

Main Methods:

  • Literature review of scientific publications and clinical trial data.
  • Analysis of pharmacological and toxicological profiles of Amphotericin B and its formulations.
  • Synthesis of information on molecular genetics, clinical efficacy, and safety.

Main Results:

  • Amphotericin B remains a cornerstone antifungal agent despite its toxicity.
  • Numerous novel formulations have been developed since the 1980s, with many achieving market approval.
  • These new formulations demonstrate reduced nephrotoxicity compared to the conventional form.

Conclusions:

  • Innovative Amphotericin B formulations offer an improved safety profile, particularly regarding kidney toxicity.
  • These advancements expand therapeutic options for managing invasive fungal infections in vulnerable patient populations.
  • Further research into the molecular and clinical aspects of these formulations continues to refine antifungal therapy.

More Related Videos

Live Imaging of Antifungal Activity by Human Primary Neutrophils and Monocytes in Response to A. fumigatus12:29

Live Imaging of Antifungal Activity by Human Primary Neutrophils and Monocytes in Response to A. fumigatus

Published on: April 19, 2017

Broth Microdilution In Vitro Screening: An Easy and Fast Method to Detect New Antifungal Compounds08:54

Broth Microdilution In Vitro Screening: An Easy and Fast Method to Detect New Antifungal Compounds

Published on: February 14, 2018

Related Concept Videos

Cryptococcal Meningitis01:27

Cryptococcal Meningitis

Cryptococcal meningitis is a life-threatening opportunistic infection predominantly associated with HIV/AIDS, accounting for over 100,000 deaths annually worldwide. However, it also affects individuals with other forms of immunosuppression, including those undergoing immunosuppressive therapy, organ transplant recipients, patients with innate immunodeficiencies, and individuals with hematological disorders. The infection is caused mainly by Cryptococcus neoformans and Cryptococcus gattii,...
Candidiasis01:20

Candidiasis

Candidiasis is a fungal infection caused by opportunistic species of Candida. It can affect various anatomical sites, including the skin, oral cavity, nails, and genitourinary tract. Among its forms, vaginal candidiasis is the most common type of mucosal infection. It typically results from the overgrowth of Candida albicans in the vaginal mucosa. Under normal conditions, C. albicans exists as a commensal organism within the vaginal microbiota, regulated by the dominance of lactobacilli, which...
Antifungal Agents01:15

Antifungal Agents

Amphotericin B is a broad-spectrum antifungal agent that exploits structural differences between fungal and mammalian cell membranes. Its amphipathic structure—featuring a hydrophobic polyene-lactone ring and a hydrophilic region containing mycosamine and carboxylic acid groups—enables selective binding to ergosterol, a sterol predominantly found in fungal plasma membranes. This selective interaction underlies the drug’s antifungal activity, although weak binding to cholesterol contributes to...